News | January 13, 2022
Metropolis Healthcare opens MedEngage Scholarship programme
The last date to apply for this program is 18th January 2022
The last date to apply for this program is 18th January 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
This test analyses samples in VTM directly without the need for RNA extraction step
The stability is led by healthy demand in the domestic and emerging markets
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Ind-Ra expects revenue growth of over 12% in 2022.
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated
